SynOx Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SynOx Therapeutics's estimated annual revenue is currently $5.1M per year.
- SynOx Therapeutics's estimated revenue per employee is $189,444
- SynOx Therapeutics's total funding is $136M.
Employee Data
- SynOx Therapeutics has 27 Employees.
- SynOx Therapeutics grew their employee count by 35% last year.
SynOx Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP, Chief Commercial Officer | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
4 | Chief Technology Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Commercial Officer | Reveal Email/Phone |
7 | VP, External Affairs and Business Development | Reveal Email/Phone |
8 | SVP, Finance and Operations | Reveal Email/Phone |
9 | SVP Finance and Operations | Reveal Email/Phone |
10 | Director Quality | Reveal Email/Phone |
SynOx Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 50 | 2% | N/A | N/A |
#2 | $5.1M | 33 | 14% | N/A | N/A |
#3 | $44.8M | 289 | N/A | N/A | N/A |
#4 | $22.1M | 61 | -28% | $325.9M | N/A |
#5 | $5.1M | 33 | 0% | N/A | N/A |
#6 | $24.6M | 159 | 10% | N/A | N/A |
#7 | $5.1M | 27 | 35% | $136M | N/A |
What Is SynOx Therapeutics?
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.
keywords:N/A$136M
Total Funding
27
Number of Employees
$5.1M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.3M | 27 | -43% | N/A |
#2 | $4.3M | 27 | 80% | N/A |
#3 | $3.9M | 27 | 17% | N/A |
#4 | $6.8M | 27 | -4% | N/A |
#5 | $3.8M | 27 | 50% | N/A |